Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Cancers|December 11, 2022
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma CellsRita Terenziani, Maricla Galetti, Silvia La Monica, et al.
Cancers|December 30, 2020
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to OsimertinibSilvia La Monica, Claudia Fumarola, Daniele Cretella, et al.
Targeted Oncology|October 19, 2023
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle RegulatorsFrancesco Volta, Silvia La Monica, Alessandro Leonetti, et al.
European Journal of Medicinal Chemistry|March 10, 2009
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell lineValentina Zuliani, Caterina Carmi, Mirko Rivara, et al.
Current Pharmaceutical Design|September 15, 2012
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancerElena Galvani, Roberta Alfieri, Elisa Giovannetti, et al.
Frontiers in Oncology|August 8, 2022
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cellsGraziana Digiacomo, Claudia Fumarola, Silvia La Monica, et al.
Frontiers in Oncology|December 23, 2024
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cellsGraziana Digiacomo, Claudia Fumarola, Silvia La Monica, et al.
Nanotoxicology|December 29, 2020
Occupational exposure to graphene and silica nanoparticles. Part II: pilot study to identify a panel of sensitive biomarkers of genotoxic, oxidative and inflammatory effects on suitable biological matricesCinzia Lucia Ursini, Anna Maria Fresegna, Aureliano Ciervo, et al.
Acta Bio-Medica : Atenei Parmensis|January 8, 2020
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumabMelissa Bersanelli, Letizia Gnetti, Augusto Vaglio, et al.
Biochemical Pharmacology|May 12, 2009
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell linesSilvia La Monica, Maricla Galetti, Roberta R Alfieri, et al.
Pageof 6